Third-generation EGFR TKIs were effective in treating EGFR T790M mutated NSCLC, but the median PFS and median overall survival (OS) of CNS metastatic patients were still shorter compared with patients without CNS metastases. Here, EGFR is linked to non-small cell lung carcinoma.